**UF BPA Appendix for the November 2016 DoD P&T Meeting**

Uniform Formulary Price Quotes and

Uniform Formulary Blanket Purchase Agreements (UF BPA)

The following Condition Sets identify the conditions under which UF BPA price quotes are to be submitted by the Company.

Pharmaceutical companies must submit a separate pricing appendix for each NDC-11.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **NDC-11** | **Drug Name** | **Strength** | **Dosage Form** | **Package Size** |
|  |  |  |  |  |

|  |
| --- |
| **DoD Uniform Formulary Class: ANTILIPIDEMICS-1** **DoD Uniform Formulary Sub-Class: PCSK9s** |
| **Class Note(s): Prior Authorization (PA) may apply.**  |
| **Step Therapy Addendum: Grandfathering:** a prior authorization process would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process. |
| **Condition Set #** | **Category\*** | **One of (X) number of brand agents** | **Military Treatment Facility &****Mail Order** |
| **Price per Unit of Measure (each, gram, mL) to** **2 decimal places** | **Price Per NDC to** **2 decimal places** |
|  |  |  |  |
| **Military Treatment Facility & Mail****171ALPKG1UFBS1X** | **Uniform Formulary** **Before Step Therapy** **Not BCF or ECF** | **1** | **$** | **$** |
| **Military Treatment Facility & Mail****171ALPKG1UFNS1M** | **Uniform** **Formulary No Step Therapy****Not BCF or ECF** | **1 or more** | **$** | **$** |
| **Military Treatment Facility & Mail****171ALPKG1UFAS1M** | **Uniform** **Formulary After Step Therapy****Not BCF or ECF** | **1 or more** | **$** | **$** |
|  |  |  |  |

**\* Only one price per category may be submitted.**

**UF ADP Appendix for the November 2016 DoD P&T Meeting**

**Condition Sets for TRICARE Retail Refund – Uniform Formulary Additional Discount Program (UF ADP)**

The following Condition Sets identify the conditions under which UF ADP quotes are to be submitted by the Company.

Pharmaceutical companies must submit a separate pricing appendix for each NDC-11.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **NDC-11** | **Drug Name** | **Strength** | **Dosage Form** | **Package Size** |
|  |  |  |  |  |

|  |
| --- |
| **DoD Uniform Formulary Class: ANTILIPIDEMICS-1** **DoD Uniform Formulary Sub-Class: PCSK9s** |
| **Class Note(s): Prior Authorization (PA) may apply.**  |
| **Step Therapy Addendum: Grandfathering:** a prior authorization process would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process. |
| **Condition Set #** | **Category\*** | **One of (X) Number of brand agents** | **Most recent Annual Non-Federal Average Manufacturer's Price (non-FAMP) per FCP Package Size\*\*** | **Current Annual Federal Ceiling Price (FCP) per FCP Package Size\*\*** | **Standard Refund per FCP Package Size\*\*** **(non-FAMP – FCP)**  | **Additional Offered****Refund (Y%) per FCP Package Size.****Percentage is Static and is a percentage of non-FAMP (non-FAMP\*Y%)** | **Total Calculated Retail Refund per FCP Package Size\*\*****((non-FAMP – FCP ) + (non-FAMP \*Y%)) = Total Calculated Refund**  |
| **171ALPKG1T2BS1X** | **Tier 2 Before Step****Therapy** | **1** | $ | $ | $ | % | $ |
| **171ALPKG1T2NS1M** | **Tier 2 No Step****Therapy** | **1 or more** | $ | $ | $ | % | $ |
| **171ALPKG1T2AS1M** | **Tier 2 After Step****Therapy** | **1 or more** | $ | $ | $ | % | $ |
|  |  |  |  |  |  |  |  |

**\* Only one price per category may be submitted.**

**\*\* Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.**